FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:954-955 September 1, 2005 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Martin, M. PubMed Citation

To the Editor: The study by Martin et al. (June 2 issue)¹ raises concern about the high rates of febrile neutropenia among patients receiving a regimen of docetaxel plus doxorubicin and cyclophosphamide (TAC). Moreover, it is not clear that the right comparator is a regimen of fluorouracil plus doxorubicin and cyclophosphamide (FAC). Dose-dense regimens have been shown to be effective and less toxic.² A recent study was prematurely terminated because of an unacceptable rate of life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel.³ We think that docetaxel-based adjuvant chemotherapy cannot be advocated as a standard approach in the management of . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.